FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946966177> ?p ?o ?g. }

• W2946966177 abstract "e20070 Background: Malignant Pleural Mesothelioma (MPM) is a rare but fatal disease related to asbestos exposure, with historic survival in the order of 9 to 17 months. Chemotherapy is associated with only a modest benefit. The advent of immunotherapy has heralded significantly improved outcomes using checkpoint inhibitors in an as yet ill-defined cohort. We aim to identify predictive and prognostic biomarkers in a series of patients (pts) with MPM and describe survival data. Methods: A retrospective audit was undertaken of pts with MPM diagnosed between 2013 and 2017 at a single tertiary centre in Melbourne, Australia (Monash Health). Data relating to patient outcomes and clinicopathological features were obtained through medical reports. Further immunostains are being performed on archived tissue for PDL-1 status. Results: 65 pts were identified, of whom 52 (80.0%) were male. Median age was 73 years (range 44-90). 52 pts were noted to be ECOG 0-1. 42 pts (64.6%) were noted to have suspected asbestos exposure. Epithelioid MPM was the most common subtype, noted in 41 pts (63.1%) (table 1). 8 pts (12.3%) presented with stage IV disease. 16 pts (24.6%) received checkpoint inhibitor therapy, with 10 (63 %) in the second/third line setting. Median overall survival (OS) was 19.8 months (95% CI 13.3-26.3) in the whole cohort.Patient characteristics associated with poor OS were: presence of weight loss (P = 0.001), chest pain (p = 0.08) and ECOG 2 (p = 0.04). Pts with sarcomatoid histology who received immune checkpoint inhibitors in any line of treatment had significantly prolonged OS compared to other histologies. 3-year survival was 80% in this group while median OS was not reached (p = 0.04). This difference was not seen with other histologies. Conclusions: The evolving landscape of treatment in MPM appears to show promise in improving OS. In this unselected case series, our data is consistent with historic controls in terms of survival and prognostic factors. The finding of significantly improved survival with immune checkpoint inhibitors in the sarcomatoid histology is exciting and warrants further exploration. Further data on PDL1 status will be presented." @default.
• W2946966177 created "2019-06-07" @default.
• W2946966177 creator A5022491020 @default.
• W2946966177 creator A5041738492 @default.
• W2946966177 creator A5047803787 @default.
• W2946966177 creator A5052018647 @default.
• W2946966177 creator A5064908504 @default.
• W2946966177 creator A5078600884 @default.
• W2946966177 date "2019-05-20" @default.
• W2946966177 modified "2023-09-27" @default.
• W2946966177 title "Treatment outcomes in malignant pleural mesothelioma: A single center experience of systemic therapies and biomarkers." @default.
• W2946966177 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e20070" @default.
• W2946966177 hasPublicationYear "2019" @default.
• W2946966177 type Work @default.
• W2946966177 sameAs 2946966177 @default.
• W2946966177 citedByCount "0" @default.
• W2946966177 crossrefType "journal-article" @default.
• W2946966177 hasAuthorship W2946966177A5022491020 @default.
• W2946966177 hasAuthorship W2946966177A5041738492 @default.
• W2946966177 hasAuthorship W2946966177A5047803787 @default.
• W2946966177 hasAuthorship W2946966177A5052018647 @default.
• W2946966177 hasAuthorship W2946966177A5064908504 @default.
• W2946966177 hasAuthorship W2946966177A5078600884 @default.
• W2946966177 hasConcept C121608353 @default.
• W2946966177 hasConcept C126322002 @default.
• W2946966177 hasConcept C142724271 @default.
• W2946966177 hasConcept C143998085 @default.
• W2946966177 hasConcept C185926286 @default.
• W2946966177 hasConcept C2777407522 @default.
• W2946966177 hasConcept C2780073493 @default.
• W2946966177 hasConcept C530470458 @default.
• W2946966177 hasConcept C71924100 @default.
• W2946966177 hasConceptScore W2946966177C121608353 @default.
• W2946966177 hasConceptScore W2946966177C126322002 @default.
• W2946966177 hasConceptScore W2946966177C142724271 @default.
• W2946966177 hasConceptScore W2946966177C143998085 @default.
• W2946966177 hasConceptScore W2946966177C185926286 @default.
• W2946966177 hasConceptScore W2946966177C2777407522 @default.
• W2946966177 hasConceptScore W2946966177C2780073493 @default.
• W2946966177 hasConceptScore W2946966177C530470458 @default.
• W2946966177 hasConceptScore W2946966177C71924100 @default.
• W2946966177 hasLocation W29469661771 @default.
• W2946966177 hasOpenAccess W2946966177 @default.
• W2946966177 hasPrimaryLocation W29469661771 @default.
• W2946966177 hasRelatedWork W2010761400 @default.
• W2946966177 hasRelatedWork W203551692 @default.
• W2946966177 hasRelatedWork W2084853935 @default.
• W2946966177 hasRelatedWork W2182565509 @default.
• W2946966177 hasRelatedWork W2195573446 @default.
• W2946966177 hasRelatedWork W2340412048 @default.
• W2946966177 hasRelatedWork W2460285199 @default.
• W2946966177 hasRelatedWork W2566982091 @default.
• W2946966177 hasRelatedWork W2591029035 @default.
• W2946966177 hasRelatedWork W2598985572 @default.
• W2946966177 hasRelatedWork W2603130183 @default.
• W2946966177 hasRelatedWork W2889770338 @default.
• W2946966177 hasRelatedWork W2911406620 @default.
• W2946966177 hasRelatedWork W2946971610 @default.
• W2946966177 hasRelatedWork W2972888625 @default.
• W2946966177 hasRelatedWork W2981612503 @default.
• W2946966177 hasRelatedWork W3028562572 @default.
• W2946966177 hasRelatedWork W3031018330 @default.
• W2946966177 hasRelatedWork W3124203459 @default.
• W2946966177 hasRelatedWork W3170692956 @default.
• W2946966177 isParatext "false" @default.
• W2946966177 isRetracted "false" @default.
• W2946966177 magId "2946966177" @default.
• W2946966177 workType "article" @default.